Dr Reddy's launches Deferasirox tablets in US market; stock up 2%

Dr. Reddy's Laboratories announces the launch of D.eferasirox Tablets for Oral Suspension, in the US market.

Dec 06, 2019 08:12 IST India Infoline News Service

Dr Reddys Laboratories
Dr. Reddy's Laboratories Ltd. today announced the launch of Deferasirox Tablets for Oral Suspension, a therapeutically equivalent generic version of Exjade® (deferasirox) Tablets for Oral Suspension, approved by the U.S. Food and Drug Administration (USFDA).

The stock is trading up more than 2% on the NSE.

The Exjade brand had US sales of approximately $113 million MAT for the most recent twelve months ending in September 2019 according to IQVIA Health*.

Dr. Reddy's Deferasirox Tablets for Oral Suspension, are available in 125 mg, 250 mg, and 500 mg dosage strengths
in bottle count sizes of 30. 

Stock view:
Dr Reddys Laboratories Ltd is currently trading at Rs2,933.65 up by Rs63.5 or 2.21% from its previous closing of Rs2,870.15 on the BSE.

Related Story